+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alizapride Market by Route Of Administration, Distribution Channel, End User, Therapeutic Indication - Global Forecast to 2030- Product Image
Alizapride Market by Route Of Administration, Distribution Channel, End User, Therapeutic Indication - Global Forecast to 2030- Product Image
Sale

Alizapride Market by Route Of Administration, Distribution Channel, End User, Therapeutic Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014922
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Alizapride Market grew from USD 7.28 billion in 2024 to USD 7.84 billion in 2025. It is expected to continue growing at a CAGR of 7.48%, reaching USD 11.23 billion by 2030.

Setting the Stage for Alizapride’s Strategic Importance

The global healthcare sector continues to pivot toward patient-centric care models, making antiemetic therapies like Alizapride increasingly relevant in both acute and chronic settings. This Executive Summary provides an authoritative overview of the current market environment, delving into key drivers, stakeholder behaviors, and emerging challenges. By framing the context for investment, innovation, and policy considerations, this introduction illuminates the broad significance of Alizapride as a versatile treatment for nausea and vomiting.

Building upon extensive primary interviews with clinicians, distributors, and regulatory experts, our analysis highlights the critical intersections between clinical efficacy, formulation advancements, and evolving delivery channels. Acknowledging the interplay of demographic shifts, aging populations, and the rise in chemotherapeutic and procedural interventions, we underscore how these factors have collectively elevated demand for reliable antiemetic options. This section sets the stage for a deeper exploration of transformative market shifts, trade policy impacts, and the segmentation insights that define growth opportunities for manufacturers, payers, and healthcare providers alike.

Navigating Fundamental Shifts in the Antiemetic Market Landscape

In recent years, the antiemetic category has experienced profound transformations driven by regulatory reforms, technological advancements, and heightened patient expectations. The transition toward value-based care has prompted healthcare systems to prioritize therapies that deliver consistent outcomes while optimizing resource utilization. Consequently, providers are increasingly adopting Alizapride in both inpatient and outpatient settings, attracted by its proven efficacy profile and adaptable administration formats.

At the same time, digitalization has redefined distribution paradigms, enabling direct-to-patient channels and online pharmacies to gain traction alongside traditional hospital and retail outlets. Telehealth platforms now facilitate prescription management and adherence monitoring, reinforcing the need for formulations that align with remote care protocols. Moreover, the growing emphasis on personalized medicine is catalyzing research into patient-tailored dosing regimens, potentially unlocking new therapeutic niches for Alizapride. As the market landscape evolves, stakeholders must navigate these shifts with agility to capitalize on emerging avenues for differentiation and growth.

Assessing the Impact of U.S. Tariffs on Alizapride Dynamics

The U.S. trade policy adjustments enacted in early 2025 have introduced a new set of challenges and recalibrations for the global pharmaceutical supply chain. Increased tariff rates on key raw materials and pharmaceutical intermediates have exerted upward pressure on manufacturing costs, compelling producers of Alizapride to reassess sourcing strategies and pricing structures. Even modest cost escalations can reverberate through distribution margins, impacting affordability and access in price-sensitive markets.

In response, forward-looking firms have pursued diversified procurement models, establishing backup supply agreements across regions to mitigate single-source dependencies. Simultaneously, contract manufacturers have accelerated process optimization initiatives to offset tariff-induced cost burdens through enhanced operational efficiency. Although short-term margins have contracted, these proactive measures have positioned the market to absorb policy fluctuations with minimal service disruptions. As trade dynamics continue to unfold, stakeholders must remain vigilant, leveraging agile planning frameworks to sustain supply continuity and uphold patient care standards.

Uncovering Critical Segmentation Patterns Shaping Usage

A nuanced understanding of administration routes reveals that intramuscular delivery remains a cornerstone of Alizapride usage, with multi-dose vials addressing high-volume institutional requirements while single-dose formats streamline point-of-care convenience. Intravenous applications have gained prominence in acute care units, where both bolus infusions for rapid symptom control and continuous infusions for sustained antiemetic coverage demonstrate clinical value. Simultaneously, the expansion of oral formulations-spanning both solutions and tablets-caters to outpatient environments and self-care scenarios, enhancing adherence through simplified dosing regimens.

Distribution channels further shape market access dynamics. Hospital pharmacies in both private and public systems continue to anchor procurement cycles, whereas the rise of direct-to-patient online pharmacies complements traditional third-party marketplaces by delivering convenience and confidentiality. Retail outlets, from expansive chain networks to niche independent pharmacies, round out the ecosystem, providing critical touchpoints for both prescribers and patients. End-user segmentation underscores the importance of targeting clinics-general and oncology alike-as well as home care models where nurse-administered and self-administered therapies empower patient autonomy. Within hospital settings, private institutions often drive early adoption, while public hospitals reinforce volume-driven demand. Therapeutic indications delineate usage patterns across chemotherapy-induced, postoperative, and pregnancy-related nausea, each demanding tailored formulations for adults, pediatric patients, day-surgery protocols, and conditions such as hyperemesis gravidarum or morning sickness. Together, these layered insights inform strategic investment in formulation development, distribution partnerships, and clinical engagement initiatives.

Decoding Regional Market Variations Across Key Geographies

Regional dynamics exert a profound influence on market trajectories, with the Americas landscape characterized by advanced healthcare infrastructures, high hospital penetration, and robust reimbursement frameworks that facilitate rapid uptake of injectable and oral antiemetic therapies. Meanwhile, Europe, the Middle East & Africa presents a mosaic of regulatory environments where mature markets prioritize cost-effectiveness analyses, and emerging economies emphasize access through generic competition and public health programs. In these regions, private hospitals often serve as innovation hubs, whereas public institutions drive volume through large-scale purchasing agreements.

Asia-Pacific stands out for its expansive growth potential, anchored by rising procedural volumes, expanding oncology centers, and evolving home-care segments. The proliferation of online pharmacies and mobile health platforms in key markets is reshaping patient pathways, while government initiatives to enhance drug availability create fertile ground for Alizapride’s entry. Cross-regional collaborations in procurement and manufacturing further underscore the strategic value of aligning global supply strategies with local market needs. Collectively, these regional insights underscore the necessity of tailored go-to-market approaches that respect each territory’s regulatory, economic, and healthcare delivery nuances.

Profiling Leading Players Driving Alizapride Innovation

The competitive arena for Alizapride features established pharmaceutical companies and agile specialty manufacturers vying to capture market share through innovation and strategic collaborations. Market leaders leverage extensive distribution networks and deep relationships with hospital systems to ensure product availability and clinician engagement. Many of these firms invest in advanced formulation research to enhance patient adherence, exploring novel oral solutions and improved injection technologies that reduce preparation complexity and administration time.

Emerging players differentiate through cost-optimization strategies, focusing on efficient manufacturing processes and lean supply chain models to deliver competitive pricing without compromising quality. Partnerships with contract research organizations and clinical research networks enable these companies to expand their evidence base, targeting new therapeutic segments such as pediatric oncology and outpatient surgery centers. Across the board, collaboration with digital health providers and pharmacy benefit managers reflects a concerted effort to integrate Alizapride into comprehensive care pathways, driving differentiation through value-added services rather than price alone.

Strategic Imperatives for Stakeholders to Seize Opportunities

Industry stakeholders should prioritize supply chain diversification to buffer against geopolitical risks and tariff-induced cost volatility, securing alternative sourcing agreements in key manufacturing hubs. Simultaneously, investment in patient-centric formulation technologies will unlock untapped market segments, particularly within home-care and self-administration models where ease of use directly correlates with adherence and clinical outcomes. Cultivating strategic alliances with telehealth providers and specialty pharmacies can streamline distribution while enhancing patient support programs.

To maximize regional opportunities, companies must align market access strategies with local reimbursement frameworks, tailoring value propositions to emphasize cost savings in mature markets and expanded access in emerging economies. Engaging early with key opinion leaders in oncology, gastroenterology, and obstetrics will strengthen clinical adoption and generate robust real-world evidence. Finally, leveraging data analytics to monitor utilization patterns and pricing sensitivities can inform dynamic pricing strategies, ensuring resilience in the face of evolving trade policies and competitive pressures.

Ensuring Rigor Through a Robust Research Framework

Our analysis draws upon a rigorous multi-phased research framework combining primary and secondary methodologies. In the secondary phase, peer-reviewed journals, regulatory filings, and industry publications were systematically reviewed to establish a comprehensive knowledge base. During the primary phase, in-depth interviews with leading clinicians, supply chain experts, and distribution executives provided firsthand insights into market drivers, adoption barriers, and emerging trends.

Quantitative data were triangulated across multiple proprietary and public databases to validate findings and ensure robustness. Segmentation analyses were performed using a top-down approach, mapping end-user behaviors and therapeutic indications to administration routes and distribution channels. Throughout the study, an iterative validation process was implemented, with draft findings reviewed by external advisors to enhance accuracy and address potential data gaps. This methodology ensures that our conclusions rest on a foundation of credible, high-fidelity information.

Synthesizing Insights to Illuminate the Path Forward

The evolving landscape of antiemetic therapies underscores the strategic value of Alizapride across a broad spectrum of clinical settings and patient populations. As healthcare systems embrace value-based care and digital distribution models, the versatility of Alizapride formulations-ranging from intramuscular and intravenous options to oral solutions and tablets-positions it as a critical component of nausea management protocols.

Trade policy shifts and regional market nuances present both challenges and opportunities, reinforcing the importance of agile supply chains, region-specific market access strategies, and ongoing engagement with clinical and distribution stakeholders. By leveraging the insights outlined in this summary, industry leaders can navigate uncertainty, optimize resource allocation, and capture emerging opportunities. The path forward demands a balanced approach, blending cost efficiency with innovation and strategic partnerships to sustain growth in the dynamic antiemetic market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Intramuscular
      • Multi Dose
      • Single Dose
    • Intravenous
      • Bolus Infusion
      • Continuous Infusion
    • Oral
      • Oral Solution
      • Tablet
  • Distribution Channel
    • Hospital Pharmacies
      • Private Hospitals
      • Public Hospitals
    • Online Pharmacies
      • Direct To Patient
      • Third Party Marketplaces
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • End User
    • Clinics
      • General
      • Oncology
    • Home Care
      • Nurse Administered
      • Self Administered
    • Hospitals
      • Private
      • Public
  • Therapeutic Indication
    • Chemotherapy Induced Nausea
      • Adult
      • Pediatric
    • Postoperative Nausea
      • Day Surgery
      • Inpatient Surgery
    • Pregnancy Related Nausea
      • Hyperemesis Gravidarum
      • Morning Sickness
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Cipla Limited
  • Aspen Pharmacare Holdings Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Alizapride Market, by Route Of Administration
8.1. Introduction
8.2. Intramuscular
8.2.1. Multi Dose
8.2.2. Single Dose
8.3. Intravenous
8.3.1. Bolus Infusion
8.3.2. Continuous Infusion
8.4. Oral
8.4.1. Oral Solution
8.4.2. Tablet
9. Alizapride Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.2.1. Private Hospitals
9.2.2. Public Hospitals
9.3. Online Pharmacies
9.3.1. Direct To Patient
9.3.2. Third Party Marketplaces
9.4. Retail Pharmacies
9.4.1. Chain Pharmacies
9.4.2. Independent Pharmacies
10. Alizapride Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. General
10.2.2. Oncology
10.3. Home Care
10.3.1. Nurse Administered
10.3.2. Self Administered
10.4. Hospitals
10.4.1. Private
10.4.2. Public
11. Alizapride Market, by Therapeutic Indication
11.1. Introduction
11.2. Chemotherapy Induced Nausea
11.2.1. Adult
11.2.2. Pediatric
11.3. Postoperative Nausea
11.3.1. Day Surgery
11.3.2. Inpatient Surgery
11.4. Pregnancy Related Nausea
11.4.1. Hyperemesis Gravidarum
11.4.2. Morning Sickness
12. Americas Alizapride Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Alizapride Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Alizapride Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Sandoz International GmbH
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.3. Sun Pharmaceutical Industries Limited
15.3.4. Dr. Reddy's Laboratories Limited
15.3.5. Hikma Pharmaceuticals PLC
15.3.6. Viatris Inc.
15.3.7. Cipla Limited
15.3.8. Aspen Pharmacare Holdings Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ALIZAPRIDE MARKET MULTI-CURRENCY
FIGURE 2. ALIZAPRIDE MARKET MULTI-LANGUAGE
FIGURE 3. ALIZAPRIDE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ALIZAPRIDE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ALIZAPRIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALIZAPRIDE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALIZAPRIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ALIZAPRIDE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ALIZAPRIDE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ALIZAPRIDE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ALIZAPRIDE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ALIZAPRIDE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALIZAPRIDE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALIZAPRIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALIZAPRIDE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALIZAPRIDE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALIZAPRIDE MARKET SIZE, BY BOLUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALIZAPRIDE MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALIZAPRIDE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALIZAPRIDE MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALIZAPRIDE MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ALIZAPRIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ALIZAPRIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ALIZAPRIDE MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ALIZAPRIDE MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ALIZAPRIDE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ALIZAPRIDE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ALIZAPRIDE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ALIZAPRIDE MARKET SIZE, BY GENERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ALIZAPRIDE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ALIZAPRIDE MARKET SIZE, BY NURSE ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ALIZAPRIDE MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ALIZAPRIDE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ALIZAPRIDE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ALIZAPRIDE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ALIZAPRIDE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ALIZAPRIDE MARKET SIZE, BY DAY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ALIZAPRIDE MARKET SIZE, BY INPATIENT SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ALIZAPRIDE MARKET SIZE, BY HYPEREMESIS GRAVIDARUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ALIZAPRIDE MARKET SIZE, BY MORNING SICKNESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ALIZAPRIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 92. CANADA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 94. CANADA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 95. CANADA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 96. CANADA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. CANADA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 98. CANADA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. CANADA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. CANADA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. CANADA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 102. CANADA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 103. CANADA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 104. CANADA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 105. CANADA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 106. CANADA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 107. CANADA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. MEXICO ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 114. MEXICO ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 115. MEXICO ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 116. MEXICO ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. MEXICO ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 119. MEXICO ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 122. MEXICO ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 123. MEXICO ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ALIZAPRIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 189. GERMANY ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 191. GERMANY ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 192. GERMANY ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. GERMANY ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. GERMANY ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. GERMANY ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 196. GERMANY ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 197. GERMANY ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. GERMANY ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 199. GERMANY ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 200. GERMANY ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. GERMANY ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 202. GERMANY ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 203. GERMANY ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 204. GERMANY ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 205. FRANCE ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. FRANCE ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 207. FRANCE ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. FRANCE ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. FRANCE ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 211. FRANCE ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 212. FRANCE ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 213. FRANCE ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. FRANCE ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. FRANCE ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 216. FRANCE ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. FRANCE ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 218. FRANCE ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 219. FRANCE ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 220. FRANCE ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 237. ITALY ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. ITALY ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 239. ITALY ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 240. ITALY ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 241. ITALY ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ITALY ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 243. ITALY ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 244. ITALY ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. ITALY ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. ITALY ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 247. ITALY ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 248. ITALY ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. ITALY ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 250. ITALY ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 251. ITALY ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 252. ITALY ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 253. SPAIN ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 255. SPAIN ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 256. SPAIN ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SPAIN ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SPAIN ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 259. SPAIN ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 260. SPAIN ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 261. SPAIN ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. SPAIN ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 264. SPAIN ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. SPAIN ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 266. SPAIN ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 267. SPAIN ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 268. SPAIN ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 308. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 317. DENMARK ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. DENMARK ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 319. DENMARK ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 320. DENMARK ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 321. DENMARK ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. DENMARK ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 323. DENMARK ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 324. DENMARK ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 325. DENMARK ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. DENMARK ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 327. DENMARK ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 328. DENMARK ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 329. DENMARK ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 330. DENMARK ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 331. DENMARK ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 332. DENMARK ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 337. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 339. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 340. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 341. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 343. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 344. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 345. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 346. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 347. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 348. NETHERLANDS ALIZAPRIDE MARKET SIZE, BY PREGNANCY RELATED NAUSEA, 2018-2030 (USD MILLION)
TABLE 349. QATAR ALIZAPRIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 350. QATAR ALIZAPRIDE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 351. QATAR ALIZAPRIDE MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 352. QATAR ALIZAPRIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 353. QATAR ALIZAPRIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 354. QATAR ALIZAPRIDE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 355. QATAR ALIZAPRIDE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 356. QATAR ALIZAPRIDE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 357. QATAR ALIZAPRIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 358. QATAR ALIZAPRIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 359. QATAR ALIZAPRIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 360. QATAR ALIZAPRIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 361. QATAR ALIZAPRIDE MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 362. QATAR ALIZAPRIDE MARKET SIZE, BY CHEMOTHERAPY INDUCED NAUSEA, 2018-2030 (USD MILLION)
TABLE 363. QATAR ALIZAPRIDE MARKET SIZE, BY POSTOPERATIVE NAUSEA, 2018-2030 (USD MILLION)
TABLE 364. QATAR ALIZAPRIDE MARKET SIZE, BY

Companies Mentioned

The companies profiled in this Alizapride market report include:
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Cipla Limited
  • Aspen Pharmacare Holdings Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.23 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Alizapride (CAS 59338-93-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Alizapride (CAS 59338-93-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast to 2030 - Product Image

Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Antiemetics Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antiemetics Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2025 - Product Image

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Market

Alizapride is a type of gastrointestinal drug used to treat symptoms of gastrointestinal disorders such as nausea, vomiting, and abdominal pain. It is a dopamine antagonist, meaning it blocks the action of dopamine in the brain, which can help reduce nausea and vomiting. Alizapride is available in both oral and injectable forms, and is often used in combination with other medications to treat more severe symptoms. It is also used to treat irritable bowel syndrome and other functional gastrointestinal disorders. Alizapride is a widely used drug in the gastrointestinal market, and is available from many pharmaceutical companies. Some of the companies that produce alizapride include Sanofi, Pfizer, Merck, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
OSZAR »